Celgene Reports First Quarter 2017 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celgene (CELG) Tops Q1 EPS by 4c; Raises Outlook
April 27, 2017 7:29 AM EDTCelgene (NASDAQ: CELG) reported Q1 EPS of $1.68, $0.04 better than the analyst estimate of $1.64. Revenue for the quarter came in at $2.95 billion versus the consensus estimate of $3.04 billion.
Our significant first quarter operational, financial and strategic progress strengthen our confidence and outlook for 2017, said Mark J. Alles, Celgenes Chief Executive Officer. Our business momentum is increasing as we continue to generate meaningful catalysts and long-term value drivers.
Net Product Sales Performance
REVLIMID® sales for the first quarter increased 20 percent to $1,884 million. Sales growth was driven primarily by... More